Skip Navigation


JAC Advance Access originally published online on October 27, 2004
Journal of Antimicrobial Chemotherapy 2004 54(6):1096-1102; doi:10.1093/jac/dkh460
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
54/6/1096    most recent
dkh460v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Adler-Moore, J. P.
Right arrow Articles by Proffitt, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adler-Moore, J. P.
Right arrow Articles by Proffitt, R. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC vol.54 no.6 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved

Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis

Jill P. Adler-Moore*, Jon A. Olson and Richard T. Proffitt{dagger}

Department of Biological Sciences, California State Polytechnic University, Pomona, CA 91768, USA

* Corresponding author. Tel: +1-909-869-4047; Fax: +1-909-869-4078; Email: jpadler{at}csupomona.edu

Objectives: This study was done to determine whether high dose AmBisome (4–20 mg/kg), given intermittently, could reduce the frequency of dosing needed to treat murine systemic candidiasis when compared with conventional daily treatment.

Methods: Mice were immunosuppressed with cyclophosphamide every 3 days, beginning day –3 before challenge with log10 5.0 cfu Candida albicans. Treatment was begun 48–72 h post-challenge with daily or intermittent dose regimens of AmBisome, followed by determination of kidney cfu for up to 1 month post-treatment.

Results: A single AmBisome dose of 4 mg/kg was as effective as four daily, 1 mg/kg treatments. A total of 8 mg/kg, given as 4 mg/kg on days 2 and 4, or as 5 mg/kg on day 2 followed by 1 mg/kg on days 3, 4, and 5, also produced comparable efficacy. While 20 mg/kg given day 2, 4 and 6 post-challenge as a 1 week loading dose, followed by one 10 mg/kg treatment on day 13, decreased the fungal burden by up to 5 logs compared with controls (log10 2.3 cfu/g and log10 7.5 cfu/g, respectively), 20 mg/kg given Monday, Wednesday and Friday for 5 weeks, reduced the fungal burden to undetectable levels (i.e. log10 1.0 cfu).

Conclusions: Significant reduction or clearance of kidney cfu, following intermittent, high dose AmBisome treatment, indicated that non-daily dosing regimens could be successfully used instead of conventional daily dosing to treat established C. albicans infection in immunosuppressed mice.

Keywords: AmBisome loading dose , antifungal therapy , intermittent AmBisome dosing


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
R. Espada, S. Valdespina, M. A. Dea, G. Molero, M. P. Ballesteros, F. Bolas, and J. J. Torrado
In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation
J. Antimicrob. Chemother., May 1, 2008; 61(5): 1125 - 1131.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
L. A. McLintock, G. Cook, T. L. Holyoake, B. L. Jones, S. E. Kinsey, and G. H. Jackson
High loading dose AmBisome(R) is efficacious and well tolerated in the management of invasive fungal infection in hematology patients
Haematologica, April 1, 2007; 92(4): 572 - 573.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. Andes, N. Safdar, K. Marchillo, and R. Conklin
Pharmacokinetic-Pharmacodynamic Comparison of Amphotericin B (AMB) and Two Lipid-Associated AMB Preparations, Liposomal AMB and AMB Lipid Complex, in Murine Candidiasis Models
Antimicrob. Agents Chemother., February 1, 2006; 50(2): 674 - 684.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. A. Olson, J. P. Adler-Moore, P. J. Smith, and R. T. Proffitt
Treatment of Candida glabrata Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or Micafungin
Antimicrob. Agents Chemother., December 1, 2005; 49(12): 4895 - 4902.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.